Scott VanderMeer, MBA

Interim CEO, CFO, Director and Co-Founder

Mr. VanderMeer is a C-level business leader in the healthcare sector, venture capital space, and private equity. He has been instrumental in forensic accounting, audits, cash management, starting businesses, and raising capital. He has founded and funded a venture capital firm International Infusion and private equity fund Infusion 51a with a focus on disruptive precision technology investments with a focus in oncology. He earned his BS in Business Marketing and MBA with a concentration in Real Estate from the University of Illinois at Chicago while playing collegiate basketball.

AR–67 is a next generation camptothecin optimized for fewer side effects and blood-brain-barrier penetration. In glioblastoma patients treated with AR-67 on a clinical trial at our center, we saw encouraging outcomes and tumor shrinkage. AR-67 was extremely well tolerated. I believe AR-67 represents a novel approach in treating this devastating disease.

AR-67 has the potential to deliver the efficacy of Camptothecins with significantly less gastrointestinal and hematological toxicity than Irinotecan. That could be a game changer for patients with gastrointestinal cancers.

AR–67 is a next generation camptothecin optimized for fewer side effects and blood-brain-barrier penetration. In glioblastoma patients treated with AR-67 on a clinical trial at our center, we saw encouraging outcomes and tumor shrinkage. AR-67 was extremely well tolerated. I believe AR-67 represents a novel approach in treating this devastating disease.

AR-67 has the potential to deliver the efficacy of Camptothecins with significantly less gastrointestinal and hematological toxicity than Irinotecan. That could be a game changer for patients with gastrointestinal cancers.